Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Protalix BioTherapeutics

Related PLX
Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF
US Stock Futures Point To Higher Open

In a report published Friday, Jefferies & Company reiterated its Hold rating on Protalix BioTherapeutics (NYSE: PLX), but slightly lowered its price target from $6.00 to $5.50.

Jefferies noted, “Narrower 3Q12 net loss of $5.5M on $5.4M revenue and ~22% lower OpEx (vs. ours of $14M). While PLX booked profit share on Elelyso sales from PFE in 3Q12 revenue (amount undisclosed), we await visibility on U.S./Israel launch progress for Elelyso in Gaucher Disease (GD). Given high hurdles to Elelyso commercialization, including established market presence of Cerezyme/Vpriv (no supply shortage), we maintain our Hold rating.”

Protalix BioTherapeutics closed on Thursday at $4.86.

Latest Ratings for PLX

Apr 2015JefferiesInitiates Coverage onBuy
May 2014JP MorganMaintainsOverweight
May 2014JefferiesMaintainsHold

View More Analyst Ratings for PLX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (PLX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters